FDA gives preliminary approval for CAR T-cell therapy

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

ST. LOUIS, Mo. _ A new treatment is on the horizon for people suffering from cancer, specifically Leukemia. The FDA has given its preliminary approval for CAR T-Cell Therapy. It’s based on a person’s own genes.

Dr. Mark Fesler, Oncologist with SLUCare and SSM Health SLU Hospital, joined us on FOX 2 News in the Morning with more.

The therapy removes healthy immune cells from the patient`s blood, has them re-programmed to attack the cancer cells and injected back into the body to fight the cancer.

It genetically alters a patient`s own cells to fight cancer, transforming them into what scientists call “a living drug” that powerfully bolsters the immune system to shut down the disease.

To learn more visit: nytimes.com/2017/07/12/health/fda-novartis-leukemia-gene-medicine.html or ssmhealth.com

Notice: you are using an outdated browser. Microsoft does not recommend using IE as your default browser. Some features on this website, like video and images, might not work properly. For the best experience, please upgrade your browser.